For Immediate Partnership Consideration: Meet Alloplex Biotherapeutics’ CEO, Dr. Frank Borriello, at BIO International Convention 2025

Seeking Strategic Partners in Cell Therapy? Alloplex Biotherapeutics, pioneering a groundbreaking non-engineered immune cell training approach to cancer immunotherapy, invites you to meet our Scientific Founder and CEO, Dr. Frank Borriello, at the BIO International Convention in Boston, June 16-19, 2025.

Why Partner with Alloplex?

• Clinically Validated Innovation: Our ENLIST immune cell training platform has yielded a lead program called SUPLEXA that shows that trained cells are exceptionally safety and display inherent single agent antitumor activity. Notably, significant Phase 1 clinical benefit across multiple solid tumors, including complete and partial responses, was observed in patients with advanced colorectal cancer and renal cell carcinoma who had exhausted standard treatment options.
• Paradigm-Shifting Technology: SUPLEXA cells dsiplay a wholly-differentiated, multi-modal (non-engineered) autologous approach to retrain a patient’s own immune cells to fight cancer using our patented ENLIST immune cell training technology, a versatile concept conceived by our Scientific Founder and CEO, Dr. Frank Borriello, is compatible with a variety of starting immune cells irrespective of engineering or whether autologous or allogeneic.
• Robust Scientific Foundation: Our robust science is supported by Dr. James A. Lederer, Chief Scientific Officer and a seasoned immunologist with expertise in immune cell characterization. His skills have been instrumental in generating the compelling scientific insights and data that delineate the SUPLEXA cell mechanisms. 
• Versatile Platform with Income-Generating Potential: The ENLIST platform can augment a variety of existing cell therapy modalities, including CAR and TIL, offering a unique opportunity to enhance the probability of success without requiring partners to abandon the significant investment made in their current strategies. Our highly-differentiated platform approach can be seamlessly integrated yielding superior second generation cell therapies. We are actively seeking partnerships to explore the diverse applications of our ENLIST technology to generate near-term value.
• Promising Phase 1 Data: Based on positive first-in-human single-agent clinical trial results in select tumor types, Alloplex is also focused on strategic partnerships to advance the development of PBMC -derived, non-engineered, autologous SUPLEXA.
• Strong Scientific Recognition: SUPLEXA’s immunomodulatory nature and promising results were recognized with a ‘Top 100’ presentation at SITC 2024. Transcriptomic and proteomic analyses yield deep insights into the enhanced proteomic networks affecting the metabolic, cytolytic, and proliferative properties of SUPLEXA cells.

Meet Our Leadership (Dr. Borriello Attending BIO 2025):

Dr. Frank Borriello, our Scientific Founder and CEO, will be available to discuss the vision underlying potential strategic partnerships at BIO International Convention 2025. The ENLIST technology, conceived by Dr. Borriello, is covered by patent and trade-secrets.

Schedule a Meeting:

We are particularly interested in connecting with companies that have an existing commitment to cell therapy.

Don’t miss this opportunity to explore a collaboration that could redefine cancer immunotherapy and create strong income-generating streams. The BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with 20,000 industry leaders from across the globe. BIO is where valuable connections are made and relationships built. The event will take place June 16-19, 2025, at the Boston Convention & Exhibition Center.

Meetings can be arranged through BIO’s proprietary BIO Partnering™ match-making platform (exclusive to Premier Access registration package holders, becoming available approximately one month before the conference) or by contacting us directly via email at office@alloplexbio.com.

We look forward to connecting with you at BIO 2025!